Retinitis Pigmentosa (RP), Usher Syndrome
Conditions
Brief summary
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are: Does NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI-001 to a placebo (a look-alike substance that contains no drug) to see if NPI-001 works to preserve vision. Participants will: Take NPI-001 or a placebo twice a day, every day for 24 months and visit the clinic 9 times for checkups and tests.
Interventions
DRUGPlacebo
Oral placebo tablet
DRUGNPI-001
Oral n-acetyl cysteine amide tablet
Sponsors
Nacuity Pharmaceuticals, Inc.
Foundation Fighting Blindness
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Able to comprehend and willing to sign an informed consent form (OCF) and adhere to the study protocol. 2. Diagnosed with RP associated with Usher syndrome. 3. EZ width ≥ 500 microns, which includes the fovea in each eye at Visit 1. 4. All edges of the EZ area in both eyes can be visualized at Visit 1 (Screening). 5. Have at least 20 detectable points on the MAIA grid in at least one eye at the Screening and Baseline visits (same eye for both visits). 6. On stable dose of medications associated with other conditions for at least one month. 7. Willing to use contraception during study (for anyone of childbearing potential).
Exclusion criteria
1. Concurrent retinal pathologies that result in vision loss or inability to fixate. 2. Intraocular surgery within the last two months or capsulotomy within the last month. 3. Current or history of uveitis, Coat's disease, diabetic retinopathy, glaucoma, herpes simplex of the eye, or currently has a cataract that prevents visualization of the posterior pole. 4. Likely to require cataract surgery within the next 12 months. 5. Unstable fixation during microperimetry in either eye at either Screening or Baseline visits. 6. Use of any other investigational new drug, or participation in another clinical trial within 12 weeks before the start of study treatment. 7. Use of N-acetylcysteine containing products in the previous 30 days prior to the baseline visit or unwilling to refrain from such supplements for the duration of the study. 8. Chronic liver or kidney disease, cystic fibrosis, severe asthma, or chronic obstructive pulmonary disease (COPD), history of thrombocytopenia not due to a reversible cause, or other blood dyscrasia. 9. Suspected liver dysfunction determined by having alanine aminotransferase (ALT), aspartate aminotransferase (AST), or bilirubin values \> 1.5 X the upper limit of normal (ULN) at screening. 10. Platelet or hemoglobin values \< 100 at screening. 11. History of known sensitivity to N-acetylcysteine or similar thiol compounds or any ingredients of NPI-001. 12. History of hypersensitivity to any medication or food resulting in systemic symptoms. 13. History of cancer (other than non-melanoma skin cancer) diagnosed or requiring treatment within the past 2 years. 14. Pregnant women or women planning to become pregnant in the next 25 months or men with partners planning to become pregnant in the next 25 months. 15. Lactating women who are breast-feeding. 16. Potential participant lives in the same household as a current participant in this study. 17. Subjects who are unwilling or unable to refrain from donation of blood from 30 days prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening until 56 days following the last study drug dose administered. 18. Inability to provide blood samples, including difficulty with venous access. 19. Any reason, in the opinion of the Principal Investigator, the participant should not participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ellipsoid Zone Area | 24 months |
Contacts
CONTACTNacuity Pharmaceuticals
Outcome results
None listed